Advanced Prostate Cancer: Therapeutic Sequencing, Outcomes, and Cost ImplicationsE. David Crawford, MD, & Kyle O. Rove, MD
Published Online: Thursday, February 7, 2013
"Now, practitioners must grapple with the increased complexity of options, indications, cost, patient selection, and side effects, and determine how best to select therapies for patients with varied health statuses and preferences. The Table provides a quick look at these new agents, cost of treatment, and overall survival. This article will briefly examine newly approved treatments for castrationresistant prostate cancer (CRPC), their indications, toxicity profiles, and cost considerations, and evaluate their potential impact on quality of life, prevention of SREs, and overall survival...
The elusive cures for many cancers will be formulated by attacking concurrent pathways using multiple agents."
www.onclive.com/publications/obtn/2013/January-2013/Advanced-Prostate-Cancer-Therapeutic-Sequencing-Outcomes-and-Cost-ImplicationsSequencing of Novel Prostate Cancer Agents Is a Work in ProgressJason M. Broderick
Published Online: Wednesday, December 26, 2012
"Based on his interpretation of the data that are available, Oh summarized the current treatment landscape in prostate cancer (Figure). He also offered some basic principles for sequencing that physicians can follow as they await further results from ongoing trials:
Start with the most effective treatment with the least toxicity.
Switch classes of therapy if there is clear evidence of resistance (eg, hormones to chemo).
Avoid overlapping treatments that may be antagonistic (eg, steroids and vaccines).
Participate in clinical trials whenever possible."
www.onclive.com/publications/obtn/2012/December-2012/Sequencing-of-Novel-Prostate-Cancer-Agents-Is-a-Work-in-Progress/1Don't forget look at FIGURE for second article on page 2.Post Edited (HOPENEVERDIE) : 2/8/2013 1:28:13 PM (GMT-7)